Brian Rifkin
@brianrifkin.bsky.social
General and Interventional Nephrologist #MedSky #NephSky, pragmatist, lover of memes/GIFs/bad dad jokes, artist, singer, NephJC editor, NephSIM mentor, GlomCon grad. Air Force veteran and type 1 diabetic (insulin pimp).
1/10 #NephJC #TenPostNephJC 💉Bicarbonate is an ICU drug that almost everyone has an opinion on. The physiology is attractive, but evidence isn’t. 🥼SODa-BIC asks if IV bicarbonate improves outcomes in ICU pts with metabolic acidosis on vasopressors. 📄 pubmed.ncbi.nlm.nih.gov/42283370/
Today, August 4, 2026, is the setting of Ray Bradbury’s short story “There Will Come Soft Rains” about a fully automated house continuing on after the family who lived there and the world around it died in a nuclear blast.
🖌️Check out the #visualabstract for the SODa-BIC trial by @danyrcal.bsky.social #NephJC www.nephjc.com/news/2026/8/...
🖌️ Echa un vistazo al #resumenvisual del ensayo SODa‑BIC realizado por @danyrcal.bsky.social #NephJC www.nephjc.com/news/2026/8/...
This week we're talkin' about IV Sodium Bicarbonate in the ICU. 💉Does it improve mortality, MAKE30... or just pH? 🥤The SODa-BIC study #NephSky #MedSky www.nephjc.com/news/soda-bic
Buffering without benefit? The SODa-BIC study — NephJC
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rath...
nephjc.com
#ASNJASN: >50% of ESRD beneficiaries are now in Medicare Advantage, yet only 1 Star measure assesses kidney care. Major gaps remain in CKD screening, nephrology referral, kidney-protective therapies, and transplant referral. kidney.pub/JASN1200?... @asnkidney.bsky.social @cervantes-lily1.bsky.social
#NephJC #TenPostNephJC FIND-CKD asks: Can we extend nsMRA cardiorenal benefits to the massive population with CKD without diabetes? Let’s FIND out! 🔍 Read the article 👇: pubmed.ncbi.nlm.nih.gov/42246672/ 1/10🧵
a young teenager with hypertension, case studies from @nejm.org enough info in table 1 to make a diagnosis! www.nejm.org/doi/full/10....
Want more?? #NephSky #NephJC 🩳FIND-CKD shorts from @CristinaDeReins Finerenone in glomerulonephritis & a pooled analysis of safety and efficacy in CKD (INFINITY) www.nephjc.com/news/2026/7/20/finerenone-shorts
Finerenone across the proteinuric CKD spectrum — NephJC
Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
nephjc.com
👀 Seek and you shall FIND 🔎 #ERA26 #NephSky FIND-CKD asks if finerenone is beneficial in patients with non-diabetic CKD. Blog by @manoleaandreea.bsky.social & @divyaveerssneph.bsky.social www.nephjc.com/news/2026/7/6/find-ckd
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role — NephJC
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effect...
nephjc.com
This is a superb educational episode Everything you wanted to know about C3G with Prof Carla Nester www.nephjc.com/freelyfilter... @freelyfiltered.bsky.social
FF94 C3 Glomerulopathy with Carla Nester — NephJC
The Valient Trial with Carla Nester
nephjc.com
The @nejm.org publishes the experience do #measles just in South Carolina www.nejm.org/doi/full/10.... Mostly unvaccinated. Mostly young. 13 hospitalized Making ID Great Again
A Regional Measles Outbreak — South Carolina, 2025–2026 | NEJM
In South Carolina, 997 measles cases occurred in the reported outbreak. In one health care system, 81 cases were identified. Most were in unvaccinated persons; 13 persons were hospitalized, and 2 ...
nejm.org
MedPage Today @medpagetoday.com quotes @brianrifkin.bsky.social et al on CKM guidelines/staging www.medscape.com/s/viewarticl... I do think CKM is a fake made up condition & the staging is a terrible idea Flozinate, glipinate - but shoving another disease and staging and guideline? Count me out!
Grumblings Over CKM Guideline Not Warranted, Experts Say
Experts push back against concerns of overmedicalization and confusing staging with the new AHA/ACC guideline on cardiovascular-kidney-metabolic syndrome.
medscape.com
🔍FIND-CKD🔎 💊Use of finerenone in non-diabetic CKD #NephJC #NephSky #ERA26 VA by @drbarbateba.bsky.social www.nephjc.com/news/2026/7/17/find-ckd-the-visual-abstract
FIND CKD: The Visual Abstract — NephJC
Is finerenone ready to move beyond diabetes? The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD. The next challenge is no...
nephjc.com
¿Está la finerenona lista para ir más allá de la diabetes? El resumen visual @drbarbateba.bsky.social @dramiliflores.bsky.social #NephJC #NephSky www.nephjc.com/news/2026/7/17/find-ckd-el-resumen-visual
FIND CKD: El Resumen Visual — NephJC
¿Está la finerenona lista para ir más allá de la diabetes? El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC...
nephjc.com
CKD outcomes can now be changed in ways that were not possible a decade ago, according to an article in #ASNCJASN. Combination therapy is moving towards preventing kidney failure and cardiovascular complications, improving safety, and enabling personalized, risk‑based care. kidney.pub/CJASN1158...
The US is experiencing a large rise in cyclosporiasis infections. Some states are seeing >20x increase in cases. Climate may be a factor. pmc.ncbi.nlm.nih.gov/articles/PMC...
The prevalence of Cyclospora cayetanensis in water: a systematic review and meta-analysis
Cyclospora cayetanensis is an emerging food- and waterborne pathogen that causes cyclosporiasis, a gastrointestinal disease in humans. The parasite is endemic in tropical and subtropical regions; howe...
pmc.ncbi.nlm.nih.gov
Five facts that you should know about the current Cyclospora outbreak.
#NephJC #TenPostNephJC. #NephSky 1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes? pubmed.ncbi.nlm.nih.gov/42240165/
🚆 TRACK trial: If thrombosis is at the core of 🫀disease...then DOACs might be helpful in high-risk CKD pts? Maybeeeee... #Nephsky Blog by @nephroseeker.medsky.social & @drsaivani.bsky.social www.nephjc.com/news/2026/7/6/on-the-right-track-rivaroxaban-to-prevent-cardiovascular-events-in-advanced-ckd
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD. — NephJC
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD. Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown ben...
nephjc.com
This week we're still catching up with #ERA26 The TRACK study 🛤️🩸 #NephJC #NephSky Check out the VA by @drsaivani.bsky.social Can low dose rivaroxaban improve CV outcomes in advanced CKD? www.nephjc.com/news/2026/7/6/track-the-visual-abstract
Track: The Visual Abstract — NephJC
Can rivaroxaban reduce cardiovascular events in advanced CKD? The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high c...
nephjc.com
🚨Another #NephJC 🩳 #NephSky The evidence keeps increasing for new therapies in IgAN🔍 Telitacicept: an APRIL/BAFF inhibitor for decreasing proteinuria in IgAN Blog by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/short/telitacicept7526
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
nephjc.com
Read the ASN Publications collection of articles highlights rapidly evolving research and treatment for kidney-heart disorders, including cardiovascular-kidney-metabolic syndrome. kidney.pub/kidneyhea...
🩳New short from Dr. Sumaiya Ahmed and @hswapnil.medsky.social #NephSky 🔮Can we use prediction models to determine who might benefit from steroids in IgAN before immunosuppression initiation? www.nephjc.com/news/2026/7/1/can-we-predict-who-benefits-from-steroids-in-igan-the-pred-igan-study
Can we predict who benefits from steroids in IgAN? The PRED-IgAN Study — NephJC
Kidney Int . 2026 Apr;109(4):738-749. doi: 10.1016/j.kint.2025.12.024. Epub 2026 Jan 20. A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment i...
nephjc.com
And @nejm.org retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!) www.nejm.org/doi/10.1056/... h/t @drjmluther.bsky.social #Avacopan #vasculitis
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. | NEJM
The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609,1 request retraction of the article because, accordi...
nejm.org
Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last mo.With link this time www.medscape.com/viewarticle/...
1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky
